Prospective screening for a genetic variant of DPD, an enzyme that catabolizes 5-FU, reduces mortality from 10% to 0% in patients with this variant and is cost-effective. Dr David Kerr is all for it.

The Obama Administration's 'moonshot' to cure cancer has drawn both admiration and skepticism among physicians. Dr Maurie Markman talks about what this ambitious effort can, and cannot, achieve.

The new Decipher genetic test may more accurately predict risk for metastasis following radical prostatectomy for prostate cancer, but will it improve outcomes?

Dr David Kerr reports on a study in which oral capecitabine beat continuous-infusion 5-FU 'fairly and squarely' in tumor control of early rectal cancer, which may prove a new standard of practice.

Are declining PSA screening rates placing men at risk? Dr Chodak discusses the latest opinions for and against routine screening.

New findings from the UK show multimodal ovarian cancer screening to be highly effective in reducing mortality, but Dr Andrew Kaunitz urges clinicians to await guidelines for routine screening.

Past AACR president Dr Carlos Arteaga describes translational studies and emerging therapies that are transforming the clinical practice of breast cancer.

Dr Saad Usmani highlights the key takeaways on newly diagnosed and relapsed/refractory myeloma from the 57th American Society of Hematology Annual Meeting.

Dr Farhad Ravandi provides an overview of the highlights in acute myeloid leukemia and acute lymphoblastic leukemia from the 2015 American Society of Hematology Annual Meeting.

Live from the ASH meeting floor, Dr Jerald Radich discussed his thoughts on therapy discontinuation for CML patients.